Rosuvastatin Calcium(row sue’ va sta tin)
Crestor
PREGNANCY CATEGORY X
Drug Classes
Antihyperlipidemic drug
HMG-CoA reductase inhibitor (statin)
Therapeutic Actions
A fungal metabolite that inhibits the enzyme (HMG-CoA) that catalyzes the first step in the cholesterol synthesis pathway, resulting in a decrease in serum cholesterol, serum LDLs (associated with increased risk of coronary artery disease) and either an increase or no change in serum HDLs (associated with decreased risk of coronary artery disease).
Indications
As an adjunct to diet in the treatment of elevated total cholesterol and LDL cholesterol and triglyceride levels in patients with primary hypercholesterolemia (familial and nonfamilial), and in patients with mixed dyslipidemia
Adjunct to diet to slow atherosclerosis progression in patients with elevated cholesterol
As an adjunct to diet for the treatment of patients with elevated serum triglyceride levels
To reduce LDL-C, total cholesterol, and ApoB in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments or if such treatments are not available
Treatment of patients with primary dysbetalipoproteinemia
Treatment of children 10–17 yr (girls must be at least 1 yr postmenarchal) with heterozygous familial hypercholesterolemia when diet therapy fails
Primary prevention of CV disease; to reduce risk of stroke, MI, and arterial revascularization procedures in patients with no clinically evident CAD but at increased risk due to age (50 and older in men, 60 and older in women), elevated C-reactive protein, and at least one other risk factor (hypertension, low HDL, smoking, family history)
Contraindications and Cautions
Contraindicated with allergy to any component of the product, active liver disease or persistent elevated serum transaminases, pregnancy, lactation.
Use cautiously with impaired hepatic function, alcoholism, renal impairment, advanced age, hypothyroidism.
Available Forms
Tablets—5, 10, 20, 40 mg
Dosages
Adults
Hypercholesteremia; mixed dyslipidemia; primary dysbetalipoproteinemia; hypertriglyceridemia; primary prevention of CAD; atherosclerosis: 5–40 mg daily PO. Usual starting dose is 10–20 mg daily with titration based on serum lipid levels, monitored every 2–4 wk until desired level is achieved.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
